Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on November 15, 2025 to three new non-executive employees under its 2025 Inducement Plan. The independent Compensation Committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4).

The grants total 2,125 time-based restricted stock units (RSUs), vesting in four equal annual installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.

CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 15, 2025 to three new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 2,125 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What did Madrigal (MDGL) announce on November 20, 2025 about employee equity awards?

Madrigal announced it granted 2,125 time-based RSUs on November 15, 2025 as inducement awards to three new non-executive employees.

How do the Madrigal (MDGL) RSUs vest and what are the conditions?

All RSUs vest in four equal annual installments on each of the first through fourth anniversaries and require continued employment at each vesting date.

Under which plan and Nasdaq rule were the Madrigal (MDGL) inducement awards approved?

The awards were granted under Madrigal’s 2025 Inducement Plan and approved under Nasdaq Listing Rule 5635(c)(4) by the independent Compensation Committee.

How many employees received inducement awards from Madrigal (MDGL) and when were they granted?

Three new non-executive employees received inducement awards, which were granted on November 15, 2025.

Will Madrigal (MDGL) RSU vesting occur if an employee leaves before a vesting date?

No; vesting of the awards is subject to each employee’s continued employment as of the applicable vesting date.